USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/13011
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMusteata, Vasile-
dc.contributor.authorStratan, Valentina-
dc.contributor.authorCatrinici, Larisa-
dc.contributor.authorMusteata, Larisa-
dc.contributor.authorDudnic, Cristina-
dc.date.accessioned2020-11-16T09:17:23Z-
dc.date.available2020-11-16T09:17:23Z-
dc.date.issued2020-10-
dc.identifier.urihttps://stiinta.usmf.md/ro/manifestari-stiintifice/zilele-universitatii-
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/13011-
dc.descriptionState University of Medicine and Pharmacy "N. Testemitanu", Institute of Oncology, Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină și Farmacie „Nicolae Testemițanu” din Republica Moldova, Ziua internațională a științei pentru pace și dezvoltareen_US
dc.description.abstractIntroduction. Chronic myeloproliferative hemopathies (CMPH) as a whole are the most common chronic leukemias in the elderlies in the structure of morbidity by hematological malignancies with primary bone marrow involvement, being characterized in the advanced stages by recurrent evolution and negative socio-economic impact.Purpose: Diagnosis identification and evaluation of management of CMPH. Material and methods. A clinico-analytical, descriptive, study was realized along with the narrative review of the international literature on the subject. The study enrolled 91 elderly patients with different phases of chronic myeloid leukemia (CML), primary myelofibrosis (PMF) and polycythemia vera (PV), who were followed up and treated at the PMSI Institute of Oncology in the period of 1995 – 2020. The following research methods were used: epidemiological, decsriptive, comparative, clinical-analytical, and cohort statistics. More than 50 reference bibliographic sources have been studied. According to the impact score, 25 relevant primary sources were identified and selected with a scientific, reproducible and transparent approach.Results. Thirty-four (37.3%) patients with PMF, 26 (28.6%) – with CML and 31 (34.1%) – with PV were diagnosed in the elderly age groups and followed up by our study. The age group of 60-69 years was more numerous in CML (22 cases, or 84.6%), constituting 25 (80.6%) cases in PV, and 25 (73.5%) cases in PMF.Thirty-four (37.3%) patients with PMF, 26 (28.6%) – with CML and 31 (34.1%) – with PV were diagnosed in the elderly age groups and followed up by our study. The age group of 60-69 years was more numerous in CML (22 cases, or 84.6%), constituting 25 (80.6%) cases in PV, and 25 (73.5%) cases in PMF. The duration of the disease from the time of onset of the initial clinical symptoms to diagnosis ranged in PMF between 1.4-7 months (median – 3.7±0.63 months), in CML between 1.5-12 months (median – 2.1±0.37 months) and in PV between 1-7 months (median – 3.8±0.54 months). Under the combination of chemotherapy and phlebotomies the clinico-hematological remission was achieved in all 31 patients with PV. The duration of response ranged from 3 to 9 months (median – 5.8 months). In all cases, the disease relapsed, with plethoric syndrome and thrombocytosis, which required the resumption of induction chemotherapy with busulfan, hydroxycarbamide, with regaining remissions. In elderly patients the overall survival over one year constituted 100%, over 5 years – 93.5%, over 10 years – 76.4% , being lower than those registered in all patients with PV (over one year – 100%, 5 years – 98.6%, 10 years – 85.9%).Conclusions. The long-term results of treatment in elderly patients with CMPH fail to those in the CMPH totality because of the development of age-related diseases and vascular accidents on the account of leuko-, thrombocytosis. The targeted treatment with TKIs remains a curative option of choice for CML patients of 60 years and more. In the elderly PV patients no significant difference was revealed in short- and longterm outcomes of chemotherapy with busulfan and hydroxycarbamide in combination with phlebotomy, being totally superior to those in PMF patients. The review of the literature shows that the patients with CMPH, especially those elderly, may endure a sizeable unfavorable impact on their employment status, which in turn may be associated with the reduced annual household income.en_US
dc.language.isoenen_US
dc.publisherUniversitatea de Stat de Medicină şi Farmacie "Nicolae Testemiţanu"en_US
dc.subjectchronic myeloproliferative hemopathiesen_US
dc.subjectelderly patientsen_US
dc.subjectdiagnosisen_US
dc.subjectmanagementen_US
dc.subjectsurvivalen_US
dc.titleManagement of elderly patients with chronic myeloproliferative hemopathies - actual issue of internal medicine and public healthen_US
dc.typeOtheren_US
Appears in Collections:Culegere de postere

Files in This Item:
File Description SizeFormat 
Musteata_Vasile.pdf172.76 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback